SavedAdd your journal

Journals / Güncel Retina Dergisi / 2019 / Cilt: 3 - Sayı: 1

Genetic and Risk Factors in Central Retinal Venous Occlusion with Macular Edema

Santral Retinal Ven Tıkanıklığı ile Maküla Ödeminde Genetik ve Risk Faktörleri

Fahrettin AKAY
Muhammed Altınışık
Yusuf Ziya GÜVEN
Pages
6–10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Other ocular risk factors are glaucoma, orbital masses with inflammation and glob trauma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Retinal venous occlusions are the most common cause of blindness after diabetic retinopathy.
📊
Key Findings & Data:Incidence of the disease increases with the age.
💡
Conclusion & Impact:Other ocular risk factors are glaucoma, orbital masses with inflammation and glob trauma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Retinal venous occlusions are the most common cause of blindness after diabetic retinopathy. Incidence of the disease increases with the age. There are systemic, genetic, and ocular risk factors that set the backround of disease. Methyltetrahydrofolate reductase (MTHFR) enzyme gene mutation (MTHFR C677T) increases the plasma levels of homocysteine and the thrombosis tendency. Factor V Leiden polymorphism FVR506Q, prothrombin (FII) G20210A, angiotensin converting enzyme (ACE) ins287del and angiotensinogen (AGT) T235M are other common gene mutations for thromboembolic events. Systemic risk factors such as hypertension, hyperlipidemia, cigarette smoking, diabetes mellitus and obesity are the diseases which make atherosclerosis. Other ocular risk factors are glaucoma, orbital masses with inflammation and glob trauma.

Özet

Retinal venöz tıkanıklıklar retinanın vasküler hastalıkları içinde diyabetik retinopatiden sonra en fazla görülen körlük sebebidir. Yaş ilerledikçe görülme oranı artar. Bu hastalığa zemin hazırlayan sistemik, genetik ve oküler risk faktörleri mevcuttur. Metiltetrahidrofolat redüktaz (MTHFR) enzim gen mutasyonu (MTHFR C677T) ile homosisteinin plazma düzeylerindeki artış tromboza eğilimi arttırır. Faktör V Leiden polimorfizmi FVR506Q, protrombin (FII)G20210A mutasyonu, anjiyotensin dönüştürücü enzim (ACE), ins287del ve anjiyotensinojen (AGT) T235M mutasyonları diğer sık bilinen gen mutasyonlarındandır. Sistemik risk faktörleri hipertansiyon, hiperlipidemi, sigara kullanımı, diabetes mellitus ve obezite gibi ateroskleroza zemin hazırlayan hastalıklardan oluşmaktadır. Glokom, orbital inflamasyon ve kitleler, glob travması oküler risk faktörlerini oluşturmaktadır.

🔖

Cite This Article

AKAY, F., Altınışık, M., GÜVEN, Y. Z. (2019). Genetic and Risk Factors in Central Retinal Venous Occlusion with Macular Edema. Güncel Retina Dergisi, Cilt: 3 - Sayı: 1, 6–10. https://ajindex.com/articles/161136

References (15)

  1. Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med 2010
  2. 363(22):2135-44. 2.Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010
  3. 8(9):1886-94. 3.Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008
  4. 49(10):4297-302. 4.Rogers S, McIntosh RL, Cheung N, Lim L, Wang J, You QS, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010
  5. 117(2):313-9 e1. 5.Zhou JQ, Xu L, Wang S, Wang YX, You QS, Tu Y et al. The 10- year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology 2013
  6. 120(4):803-8. 6.O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008
  7. 126(5):692-9. 7.Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001
  8. 131(1):61-77. 8.Gao W, Wang YS, Zhang P, Wang HY. MTHFR C677T mutation in central retinal vein occlusion: a case-control study in Chinese population. Thromb Res 2008
  9. 121(5):699-703. 9.Lattanzio R, Sampietro F, Ramoni A, Fattorini A, Brancato R, D’Angelo A. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina 2006
  10. 26(1):65-70. 10.Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function. Curr Drug Metab 2005
  11. 6(1):27-36. 11.Martin SC, Rauz S, Marr JE, Martin N, Jones AF, Dodson PM. Plasma total homocysteine and retinal vascular disease. Eye (Lond) 2000
  12. 14 ( Pt 4):590-3. 12.Lahiri KD, Dutta J, Datta H, Das HN. Hyperhomocysteinemia, as an independent risk factor for retinal venous occlusion in an Indian population. Indian J Clin Biochem 2013
  13. 28(1):61-4. 13.McGimpsey SJ, Woodside JV, Bamford L, Gilchrist SE, Graydon R, McKeeman GC et al. Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci 2005
  14. 46(12):4712-6. 14.Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001
  15. 85(11):1313-5. 15.De Polo L, Maltese P